Business Description
Laboratorios Farmaceuticos Rovi SA
ISIN : ES0157261019
Share Class Description:
LABFF: Ordinary SharesTotal Employee Number:
2,188Compare
Compare
Traded in other countries / regions
ROVI.Spain0ILL.UKROVIN.Mexico41L.Germany1ROVI.ItalyROVI.AustriaLABFF.USA IPO Date
2020-12-01Description
Laboratorios Farmaceuticos Rovi SA is engaged in the production and sale of pharmaceutical products, including products developed in-house. Its activities include the sale of its own pharmaceutical products, the distribution of products under licences granted by other laboratories, and the provision of manufacturing services to third parties. Its operating segments are Manufacturing, which generates the maximum revenue from service contracts related to the finalisation of pharmaceutical product production processes for external entities and the manufacture of products to be marketed by other group companies, Marketing, and Other. It operates in Spain, the European Union, and other countries.
Financial Strength
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.85 | |||||
Equity-to-Asset | 0.73 | |||||
Debt-to-Equity | 0.17 | |||||
Debt-to-EBITDA | 0.55 | |||||
Interest Coverage | 64.33 | |||||
Piotroski F-Score | 5/9 | |||||
Altman Z-Score | 10.01 | |||||
Beneish M-Score | -2.4 | |||||
WACC vs ROIC | ||||||
Growth Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -1.7 | |||||
3-Year EBITDA Growth Rate | -7.1 | |||||
3-Year EPS without NRI Growth Rate | -9.4 | |||||
3-Year FCF Growth Rate | -12.5 | |||||
3-Year Book Growth Rate | 9.4 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 18.58 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 10.74 |
Momentum Rank
2/10
| Name | Current | Vs Industry | Vs History |
|---|
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 3.66 | |||||
Quick Ratio | 1.8 | |||||
Cash Ratio | 0.66 | |||||
Days Inventory | 434.73 | |||||
Days Sales Outstanding | 76 | |||||
Days Payable | 118.45 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Dividend Growth Rate | -0.7 | |||||
3-Year Average Share Buyback Ratio | 0.8 | |||||
Shareholder Yield % | 1.48 |
Profitability Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 65.47 | |||||
Operating Margin % | 23.58 | |||||
Net Margin % | 17.79 | |||||
EBITDA Margin % | 27.89 | |||||
FCF Margin % | 15.47 | |||||
OCF Margin % | 24.56 | |||||
ROE % | 21.17 | |||||
ROA % | 14.69 | |||||
ROIC % | 18.53 | |||||
3-Year ROIIC % | -37.66 | |||||
ROC (Joel Greenblatt) % | 27.67 | |||||
ROCE % | 23.96 | |||||
Years of Profitability over Past 10-Year | 10 |
GF Value Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 21.78 | |||||
Forward PE Ratio | 29.08 | |||||
PE Ratio without NRI | 21.72 | |||||
Shiller PE Ratio | 24.55 | |||||
Price-to-Owner-Earnings | 25.43 | |||||
PEG Ratio | 1.49 | |||||
PS Ratio | 3.87 | |||||
PB Ratio | 4.26 | |||||
Price-to-Tangible-Book | 4.49 | |||||
Price-to-Free-Cash-Flow | 25.18 | |||||
Price-to-Operating-Cash-Flow | 15.84 | |||||
EV-to-EBIT | 16.53 | |||||
EV-to-EBITDA | 14.03 | |||||
EV-to-Forward-EBITDA | 27.75 | |||||
EV-to-Revenue | 3.91 | |||||
EV-to-Forward-Revenue | 6.39 | |||||
EV-to-FCF | 25.44 | |||||
Price-to-GF-Value | 1.1 | |||||
Price-to-Projected-FCF | 1.53 | |||||
Price-to-DCF (Earnings Based) | 0.87 | |||||
Price-to-DCF (FCF Based) | 1.01 | |||||
Price-to-Median-PS-Value | 1.2 | |||||
Price-to-Peter-Lynch-Fair-Value | 1.49 | |||||
Price-to-Graham-Number | 2.08 | |||||
| Price-to-Net-Current-Asset-Value | 10 | |||||
Earnings Yield (Greenblatt) % | 6.05 | |||||
FCF Yield % | 3.97 | |||||
Forward Rate of Return (Yacktman) % | 18.09 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with OTCPK:LABFF
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Laboratorios Farmaceuticos Rovi SA Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 863.285 | ||
| EPS (TTM) ($) | 3.011 | ||
| Beta | -0.0522 | ||
| 3-Year Sharpe Ratio | 0.53 | ||
| 3-Year Sortino Ratio | 7.18 | ||
| Volatility % | 1.21 | ||
| 14-Day RSI | - | ||
| 14-Day ATR ($) | - | ||
| 20-Day SMA ($) | 90.61 | ||
| 12-1 Month Momentum % | - | ||
| 52-Week Range ($) | 90.61 - 90.61 | ||
| Shares Outstanding (Mil) | 51.14 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Laboratorios Farmaceuticos Rovi SA Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Laboratorios Farmaceuticos Rovi SA Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-06 | In 118 days | ||
| Second quarter earnings conference call for 2026 | 2026-07-24 10:00 | In 14 days | ||
| Second quarter earnings results for 2026 | 2026-07-24 | In 13 days | ||
| EUR 0.959400 Cash Dividend | 2026-07-13 | In 2 days | ||
| General meeting for 2025 | 2026-06-17 11:00 | 90.61 (+0.00%) | ||
| First quarter earnings conference call for 2026 | 2026-05-06 11:00 | 90.61 (+0.00%) | ||
| First quarter earnings results for 2026 | 2026-05-06 | 90.61 (+0.00%) | ||
| Fourth quarter earnings conference call for 2025 | 2026-02-25 04:00 | 90.61 (+0.00%) | ||
| Annual report for 2025 | 2026-02-25 | 90.61 (+0.00%) | ||
| Fourth quarter earnings results for 2025 | 2026-02-25 | 90.61 (+0.00%) |
Show
Entries
Laboratorios Farmaceuticos Rovi SA Frequently Asked Questions
What is Laboratorios Farmaceuticos Rovi SA(LABFF)'s stock price today?
The current price of LABFF is $90.61. The 52 week high of LABFF is $90.61 and 52 week low is $90.61.
When is next earnings date of Laboratorios Farmaceuticos Rovi SA(LABFF)?
The next earnings date of Laboratorios Farmaceuticos Rovi SA(LABFF) is 2026-07-24 Est..
Does Laboratorios Farmaceuticos Rovi SA(LABFF) pay dividends? If so, how much?
Laboratorios Farmaceuticos Rovi SA(LABFF) does not pay dividend.
Guru Commentaries on OTCPK:LABFF
No articles.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Articles on Laboratorios Farmaceuticos Rovi SA
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers